Nantes, October 2nd, 2019
The board of Global Morpho Pharma SAS has the pleasure to announce that François Zimmermann will take over the position of Chief Executive Officer of the company. François will be located in Nantes together with his growing expert team. The company will move to a new office shortly.
Pierre-Marie Lemer, chairman of the Global Morpho Pharma board stated that “as a startup company, Global Morpho Pharma needs to be driven by a young entrepreneur and François with his past experience as project manager in Switzerland and Canada presented an ideal profile to take on this responsibility. He will be supported in his new role by the entire board as well as all the experts who have been hired recently”.
François’ main duty will be to develop the network of production, sales and distribution of therapeutic radionuclides, with a priority given to the supply of non-carrier added Lutetium-177 and (Actinium-227 free) Actinium-225 which are expected to be the radionuclides with the largest applications in nuclear medicine by 2022-2025.
Pierre-Marie Lemer and the board would like to thank Richard Zimmermann for taking on the role of interim CEO since the company was created (January 2018) and for the progress the company has achieved over this period. Richard will remain involved as a member of the board and special advisor to the CEO.
Global Morpho Pharma will have a booth at the EANM Barcelona congress (Booth #101 – October 12-15, 2019) and we would be pleased to introduce our new CEO to you at the congress.
About Global Morpho Pharma
Global Morpho Pharma SAS is a French company created early 2018 that aims at developing, distributing and selling radionuclides and radiopharmaceuticals under Good Manufacturing Practice (GMP) quality for the benefit of the patients and the expanding nuclear medicine industry. Global Morpho Pharma intends to become one of the major and global suppliers of pharmaceutical grade doses of radionuclides and radiolabeled drugs for the pharmaceutical industry and will primarily focus on non-carrier added Lutetium-177 and Actinium-225.
More info: www.morphopharma.com
About nca Lutetium-177
No-carrier added Lutetium-177 is a beta emitter (electrons) with an intermediate range of action in body tissues. Its action spectrum, combined with the absence of long half-life radioactive impurities, makes it an effective isotope for the treatment of a wide range of cancers when coupled with vector molecules targeting specific cancer cell biomarkers. The portfolio of nca Lutetium-177 molecules is rich and includes treatments in advanced clinical trials for prostate, kidney and neuroendocrine tumors, just to name a few.
Actinium-225 is a short-range alpha emitter (helium nucleus) that deposits a large amount of energy into the surrounding tissues. It is therefore very effective in damaging the double strand of the DNA helix in cancer cells, resulting in effective destruction of these cells. Once attached to a vector selectively targeting a cancer cell, it will mainly deposit its energy in the direct vicinity of these cells. There is a wide range of new treatments at the preclinical and clinical trial stages that require a reliable supply of Actinium-225 free of long half-life radioactive impurities, such as Actinium-227.